Last reviewed · How we verify

NCT03841955

Safety and Effectiveness of CATHTONG™ II PICC

Completed NA Last updated 16 June 2021
What this trial tests

NA trial testing PICC with high pressure tolerance in Cancer in 144 participants. Completed in 30 October 2020.

Timeline
17 October 2018
Primary endpoint
20 September 2019
30 October 2020

Quick facts

Lead sponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment144
Start date17 October 2018
Primary completion20 September 2019
Estimated completion30 October 2020
Sites4 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 80, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial is a prospective, multi-centre, open, parallel and comparative non-inferior trial design.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03841955.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing